ViroGates Corporate Profile
ViroGates is an international biotech company headquartered in Copenhagen, Denmark. ViroGates develops and distributes prognostic products for healthcare management with a single goal in mind: To identify risk patients early and improve the lives of seriously infected people globally. The novel ViroGates method involves the measurement of a protein found in every individual known as soluble urokinase Plasminogen Activator Receptor (suPAR). suPAR has a unique value as prognostic biomarker: Independent of the respective condition, an elevated suPARnostic® level carries a negative prognostic value and can thus be a master alarm for patient risk status. In clinical practice suPARnostic®’s application should be in patient triaging in critical care as well as for monitoring of treatment efficacy and success. suPARnostic®’s prognostic value has been exemplified in various infectious conditions through a number of studies, these include sepsis, tuberculosis and HIV.
ViroGates’ first commercial product - suPARnostic® - is an ELISA-based test kit for the quantitative determination of suPAR in human EDTA plasma. suPARnostic® holds the CE/IVD mark and provides a simple, cost-effective and highly transportable clinical monitoring tool. ViroGates has launched suPARnostic® in certain European, African and Asian countries. Further products are being developed: A lateral flow rapid test - suPARnostic® Quick - is in final stages of development as well as line extensions to the current kit.
Press Releases
Latest Press Releases:
2009-10-14
ViroGates changes management structure and gears up for strong sales focus
20091014 Press Release ViroGates.pdf (13.11 KB)
2009-09-17
Groundbreaking results from hospital trial:
A simple blood test predicts mortality in discharged patients
20090917 Press Release ViroGates.pdf (338.61 KB)
For more Press Releases, please see our Press Release Archive
Media Queries
Please contact May Britt Dyvelkov, CFO & Administrative Director (+45 2448 8327 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it ).
